(AGENPARL) - Roma, 5 Novembre 2025 -

(AGENPARL) – Wed 05 November 2025 Lund, Sweden, November 5. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA),
today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, and Evan
Ballantyne, CFO, will be attending the 2025 Truist Securities Biopharma
Symposium in New York, Thursday 6 November. In addition, Aguiar-Lucander will be
presenting at two other key industry events, the Stifel 2025 Healthcare
Conference in New York, Tuesday 11 November, and the SEB Healthcare Seminar
2025, in Stockholm, Thursday 13 November.
If you are interested in meeting with Hansa’s management for one-on-one
Event: 2025 Truist Securities Biopharma Symposium
Date and Place: Thursday 6 November, Lotte New York Palace Hotel, New York.
Event: Stifel 2025 Healthcare Conference
Date, Time, and Place: Tuesday 11 November, 16:00 PM EST, Lotte New York Palace
Hotel, New York.
Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma
Webcast Link: Click here for
webcast (https://event.summitcast.com/view/cwkmPXkC4dosg6MoG95rxb/GyjexFFFYMN3EtS
Tkiir25)
Event: SEB Healthcare Seminar 2025 – Fireside chat & Q&A
Date, Time, and Place: Thursday 13 November, 14:20-15:00 PM CET,
Kungsträdgården, Stockholm.
Moderator: Christopher Uhde, Senior Pharma & Biotech Equity Analyst, SEB
Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Kerstin Falck, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on
a mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with
redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations
in Europe and the U.S. The company is listed on Nasdaq Stockholm under the
ticker HNSA. Find out more at www.hansabiopharma.com and follow us on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/2uuRCFgeTUnvT4eJnSJYAdHWMnTLadfVsysWBCmsTesGMaP3ovc3ndfwe25Rqft1KwbfVbLZxFCwmjF1WCQAkY5Cs3fqUqEJtYqBUjRg7s43rE.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/2uuRCFgeTUnvT4eJnSJYAdHWMnTLadfVsysWBCmsTesGMaP3ovc3ndfwe25Rqft1KwbfVbLZxFCwmjF1WCQAkY5Cs3fqUqEJtYqBUjRg7s43rE.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content